1. Home
  2. BCTXW vs SRPT Comparison

BCTXW vs SRPT Comparison

Compare BCTXW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCTXW
  • SRPT
  • Stock Information
  • Founded
  • BCTXW N/A
  • SRPT 1980
  • Country
  • BCTXW Canada
  • SRPT United States
  • Employees
  • BCTXW N/A
  • SRPT N/A
  • Industry
  • BCTXW Biotechnology: Pharmaceutical Preparations
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCTXW Health Care
  • SRPT Health Care
  • Exchange
  • BCTXW Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • BCTXW N/A
  • SRPT N/A
  • IPO Year
  • BCTXW N/A
  • SRPT 1997
  • Fundamental
  • Price
  • BCTXW $0.12
  • SRPT $107.95
  • Analyst Decision
  • BCTXW
  • SRPT Buy
  • Analyst Count
  • BCTXW 0
  • SRPT 22
  • Target Price
  • BCTXW N/A
  • SRPT $174.64
  • AVG Volume (30 Days)
  • BCTXW 90.9K
  • SRPT 799.4K
  • Earning Date
  • BCTXW 03-14-2025
  • SRPT 02-26-2025
  • Dividend Yield
  • BCTXW N/A
  • SRPT N/A
  • EPS Growth
  • BCTXW N/A
  • SRPT N/A
  • EPS
  • BCTXW N/A
  • SRPT 1.22
  • Revenue
  • BCTXW N/A
  • SRPT $1,640,348,000.00
  • Revenue This Year
  • BCTXW N/A
  • SRPT $53.06
  • Revenue Next Year
  • BCTXW N/A
  • SRPT $68.79
  • P/E Ratio
  • BCTXW N/A
  • SRPT $88.50
  • Revenue Growth
  • BCTXW N/A
  • SRPT 48.45
  • 52 Week Low
  • BCTXW $0.10
  • SRPT $102.16
  • 52 Week High
  • BCTXW $0.13
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • BCTXW N/A
  • SRPT 33.84
  • Support Level
  • BCTXW N/A
  • SRPT $109.52
  • Resistance Level
  • BCTXW N/A
  • SRPT $114.41
  • Average True Range (ATR)
  • BCTXW 0.00
  • SRPT 3.36
  • MACD
  • BCTXW 0.00
  • SRPT -0.50
  • Stochastic Oscillator
  • BCTXW 0.00
  • SRPT 2.73

About BCTXW BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: